Share on StockTwits

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) have been given an average rating of “Hold” by the fifteen ratings firms that are presently covering the company, AnalystRatings.Net reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $88.14.

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded down 0.08% on Friday, hitting $73.00. 247,217 shares of the company’s stock traded hands. Vertex Pharmaceuticals has a 1-year low of $58.06 and a 1-year high of $89.96. The stock has a 50-day moving average of $68.10 and a 200-day moving average of $72.9. The company’s market cap is $17.242 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Thursday, May 1st. The company reported ($0.65) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.68) by $0.03. The company had revenue of $118.50 million for the quarter, compared to the consensus estimate of $134.46 million. During the same quarter in the prior year, the company posted $0.03 earnings per share. The company’s quarterly revenue was down 63.9% on a year-over-year basis. On average, analysts predict that Vertex Pharmaceuticals will post $-2.81 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on VRTX shares. Analysts at HC Wainwright reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Thursday. Separately, analysts at Zacks downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Wednesday, May 21st. They now have a $72.30 price target on the stock. Finally, analysts at TheStreet downgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, May 6th.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.